Medicine
Livmarli 9.5 mg/mL oral solution
Livmarli 9.5 mg/mL oral solution is a prescription medicine containing Maralixibat for oral use, marketed by Mirum Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store unopened LIVMARLI oral solution and tablets between 20°C and 25°C (68°F…
Key facts
- Active ingredient (INN)
- Maralixibat
- Brand
- Livmarli
- Strength
- 9.5 mg/mL
- Dosage form
- Oral solution
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Mirum Pharmaceuticals
- Manufacturer
- Mirum Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store unopened LIVMARLI oral solution and tablets between 20°C and 25°C (68°F and 77°F), excursion permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A05AX04 Maralixibat
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 September 2021
- Identifiers
- RxCUI 2571079, 2571085, 2690990 +7DailyMed set ID 64000394-1ef6-4e76-8ba8-11f25ba1b167NDC 79378-110Application NDA214662
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 30 mL in 1 bottle | 79378-110-01 | Mirum Pharmaceuticals | 29 September 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Maralixibat
Clinical summary
Maralixibat is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS), among other approved uses. MedsAcross supplies Maralixibat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MaralixibatFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Livmarli prescribing information (Mirum Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Livmarli: European public assessment report (EPAR) · European Medicines Agency
Need Livmarli 9.5 mg/mL oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.